232 related articles for article (PubMed ID: 32568176)
21. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene.
Meloni G; Diverio D; Vignetti M; Avvisati G; Capria S; Petti MC; Mandelli F; Lo Coco F
Blood; 1997 Aug; 90(3):1321-5. PubMed ID: 9242568
[TBL] [Abstract][Full Text] [Related]
22. Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia.
Rzepiel A; Kutszegi N; Gézsi A; Sági JC; Egyed B; Péter G; Butz H; Nyírő G; Müller J; Kovács GT; Szalai C; Semsei ÁF; Erdélyi DJ
J Transl Med; 2019 Nov; 17(1):372. PubMed ID: 31727091
[TBL] [Abstract][Full Text] [Related]
23. WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation.
Zhong L; Wei L; Chen J; Huang X; Gong Y; Lu Y
Mol Diagn Ther; 2015 Aug; 19(4):205-12. PubMed ID: 26138637
[TBL] [Abstract][Full Text] [Related]
24. Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study.
Imaizumi M; Tawa A; Hanada R; Tsuchida M; Tabuchi K; Kigasawa H; Kobayashi R; Morimoto A; Nakayama H; Hamamoto K; Kudo K; Yabe H; Horibe K; Tsuchiya S; Tsukimoto I
Br J Haematol; 2011 Jan; 152(1):89-98. PubMed ID: 20735397
[TBL] [Abstract][Full Text] [Related]
25. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
[TBL] [Abstract][Full Text] [Related]
26. Monitoring minimal residual disease and predicting relapse in APL by quantitating PML-RARalpha transcripts with a sensitive competitive RT-PCR method.
Tobal K; Moore H; Macheta M; Yin JA
Leukemia; 2001 Jul; 15(7):1060-5. PubMed ID: 11455974
[TBL] [Abstract][Full Text] [Related]
27. The c-Myc-regulated miR-17-92 cluster mediates ATRA-induced APL cell differentiation.
Yu X; Hu Y; Wu Y; Fang C; Lai J; Chen S; Li Y; Zeng C; Zeng Y
Asia Pac J Clin Oncol; 2019 Dec; 15(6):364-370. PubMed ID: 31264378
[TBL] [Abstract][Full Text] [Related]
28. Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.
Santamaría C; Chillón MC; Fernández C; Martín-Jiménez P; Balanzategui A; García Sanz R; San Miguel JF; González MG
Haematologica; 2007 Mar; 92(3):315-22. PubMed ID: 17339180
[TBL] [Abstract][Full Text] [Related]
29. [Application of CD123 in detection of minimal residual disease in acute promyelocytic leukemia].
Wang YZ; Chang Y; Zhu HH; Qin YZ; Li JL; Fu JY; Li LD; Chen SS; Huang XJ; Lu DP; Liu YR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):427-32. PubMed ID: 16800913
[TBL] [Abstract][Full Text] [Related]
30. Serum MicroRNA-370 as a potential diagnostic and prognostic biomarker for pediatric acute myeloid leukemia.
Lin X; Wang Z; Wang Y; Feng W
Int J Clin Exp Pathol; 2015; 8(11):14658-66. PubMed ID: 26823789
[TBL] [Abstract][Full Text] [Related]
31. Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations.
Ferrari A; Bussaglia E; Úbeda J; Facchini L; Aventin A; Sierra J; Nomdedéu JF
Hematol Oncol; 2012 Sep; 30(3):109-14. PubMed ID: 21812014
[TBL] [Abstract][Full Text] [Related]
32. Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia.
Zhi F; Cao X; Xie X; Wang B; Dong W; Gu W; Ling Y; Wang R; Yang Y; Liu Y
PLoS One; 2013; 8(2):e56718. PubMed ID: 23437222
[TBL] [Abstract][Full Text] [Related]
33. Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia.
Reiter A; Lengfelder E; Grimwade D
Acta Haematol; 2004; 112(1-2):55-67. PubMed ID: 15179005
[TBL] [Abstract][Full Text] [Related]
34. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups.
Mandelli F; Diverio D; Avvisati G; Luciano A; Barbui T; Bernasconi C; Broccia G; Cerri R; Falda M; Fioritoni G; Leoni F; Liso V; Petti MC; Rodeghiero F; Saglio G; Vegna ML; Visani G; Jehn U; Willemze R; Muus P; Pelicci PG; Biondi A; Lo Coco F
Blood; 1997 Aug; 90(3):1014-21. PubMed ID: 9242531
[TBL] [Abstract][Full Text] [Related]
35. Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
Grimwade D; Jovanovic JV; Hills RK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):53-61. PubMed ID: 24907017
[TBL] [Abstract][Full Text] [Related]
36. Expression of bone morphogenetic proteins in acute promyelocytic leukemia before and after combined all trans-retinoic acid and cytotoxic treatment.
Grcević D; Marusić A; Grahovac B; Jaksić B; Kusec R
Leuk Res; 2003 Aug; 27(8):731-8. PubMed ID: 12801531
[TBL] [Abstract][Full Text] [Related]
37. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome.
Yamamoto de Almeida L; Pereira-Martins DA; Lima ASG; Baggio MS; de Araujo Koury LC; Lange AP; Bassi SC; Scheucher PS; Rego EM
BMC Cancer; 2020 Aug; 20(1):821. PubMed ID: 32859169
[TBL] [Abstract][Full Text] [Related]
39. Minimal residual disease in acute myelogenous leukemia with PML/RAR alpha or AML1/ETO mRNA and phenotypic analysis of possible T and natural killer cells in bone marrow.
Inokuchi K; Iwakiri R; Futaki M; Hanawa H; Tanosaki S; Nomura T; Dan K
Leuk Lymphoma; 1998 May; 29(5-6):553-61. PubMed ID: 9643569
[TBL] [Abstract][Full Text] [Related]
40. [Detection of the PML/RAR alpha rearrangement in acute promyelocytic leukemia using a reverse PCR method].
Barragán E; Bonanad S; López JA; Martín G; Martínez J; Sanz GF; Gomis F; Pérez ML; Senent ML; Larrea L; Bolufer P; Sanz MA
Sangre (Barc); 1996 Jun; 41(3):189-94. PubMed ID: 8755206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
